What is the recommended dose of 3% (three percent) normal saline for a patient with subdural hematoma (SDH) and hyponatremia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Dose of 3% Normal Saline in SDH Patients with Hyponatremia

For patients with subdural hematoma (SDH) and hyponatremia, administer 3% hypertonic saline at a dose of 250 mOsm in an infusion over 15-20 minutes to treat threatened intracranial hypertension or signs of brain herniation after controlling secondary brain insults. 1

Assessment and Initial Management

  • Evaluate symptom severity and acuity of hyponatremia onset to determine appropriate treatment approach 2
  • For severe symptomatic hyponatremia (mental status changes, seizures, coma), administer 3% hypertonic saline with an initial goal to correct sodium by 6 mmol/L over 6 hours or until severe symptoms resolve 2, 3
  • For patients with SDH, hypertonic saline is effective in reducing intracranial pressure (ICP) with maximum effect observed after 10-15 minutes and lasting for 2-4 hours 1

Dosing Recommendations

  • For acute treatment of threatened intracranial hypertension: 250 mOsm of 3% hypertonic saline infused over 15-20 minutes 1
  • For severe symptomatic hyponatremia:
    • Initial bolus: 100-250 mL of 3% hypertonic saline 4, 5
    • A 250 mL bolus is more effective than 100 mL for achieving a rise in serum sodium ≥5 mmol/L within 4 hours (52% vs 32% success rate) 5
    • May repeat bolus up to two more times if symptoms persist, but third bolus increases risk of overcorrection 4

Correction Rate Guidelines

  • Limit total correction to no more than 8 mmol/L in 24 hours to prevent osmotic demyelination syndrome 2, 3
  • For patients with advanced liver disease, alcoholism, malnutrition, or prior encephalopathy, use more cautious correction rates (4-6 mmol/L per day) 2
  • Monitor serum sodium every 2 hours during initial correction for severe symptoms 2

Special Considerations for SDH Patients

  • Subdural hematoma can cause syndrome of inappropriate ADH secretion (SIADH), leading to hyponatremia 6
  • Hypertonic saline is particularly beneficial in SDH patients as it reduces cerebral edema while correcting hyponatremia 1
  • Continuous infusion of 500 mL of 3% sodium chloride solution over 6 hours has been shown effective for hyponatremic encephalopathy without causing cerebral demyelination 7

Monitoring and Safety

  • Calculate sodium deficit using formula: Desired increase in Na (mEq/L) × (0.5 × ideal body weight in kg) 2
  • Measure serum sodium within 6 hours of administration if bolus doses are given 1
  • Do not re-administer hypertonic saline until serum sodium concentration is <155 mmol/L 1
  • Watch for signs of osmotic demyelination syndrome (dysarthria, dysphagia, oculomotor dysfunction, quadriparesis) typically occurring 2-7 days after rapid correction 2

Common Pitfalls to Avoid

  • Overly rapid correction exceeding 8 mmol/L in 24 hours can lead to osmotic demyelination syndrome 2
  • Inadequate monitoring during active correction 2
  • Failing to recognize and treat the underlying cause of hyponatremia 2
  • Prophylactic administration of hypertonic saline to patients with no evidence of intracranial hypertension is not superior to crystalloids 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Sodium Imbalance

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment of Hyponatremia in SIADH

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Treatment of hyponatremic encephalopathy with a 3% sodium chloride protocol: a case series.

American journal of kidney diseases : the official journal of the National Kidney Foundation, 2015

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.